Shionogi & Co., Ltd. - Unsponsored ADR (SGIOY)

Overview

Shionogi & Co., Ltd., founded in 1878 and headquartered in Osaka, Japan, originally operated as Shionogi Shoten Co., Ltd. before evolving its name in 1943. The company is deeply involved in the pharmaceutical industry, specializing in the research, development, manufacturing, and distribution of pharmaceuticals, diagnostic reagents, and medical devices primarily in Japan. Shionogi & Co., Ltd. is known for its significant contributions towards addressing complex health challenges, focusing on a range of treatments from infectious diseases to chronic conditions.

Products and Services

Fetroja: A treatment for multidrug-resistant gram-negative bacterial infections.

Cabenuva and Apretude: Includes anti-HIV drugs and prophylactics for HIV prevention.

Xocova: An oral treatment for COVID-19, contributing to the global effort against the pandemic.

Finibax: A carbapenem antibiotic designed for severe infections.

Xofluza: An antiviral drug targeting influenza, aiming to reduce the severity and duration of flu symptoms.

Tivicay: Another anti-HIV drug, part of Shionogi's effort to combat HIV/AIDS.

S-872600: An influenza nasal vaccine under development, representing Shionogi's innovative approach to vaccination.

S-875670: A COVID-19 nasal vaccine candidate, showcasing Shionogi's dedication to pandemic preparedness and response.

S-540956: A nucleic acid adjuvant, enhancing the effectiveness of vaccines.

Olorofim: Designed for the treatment of invasive aspergillosis, a serious fungal infection.

Cefiderocol: Targets aerobic gram-negative bacterial infections, addressing a critical need in infectious disease treatment.

Ensitrelvir: Aimed at treating and preventing COVID-19, highlighting Shionogi's ongoing commitment to pandemic response.

Baloxavir: An influenza virus infection treatment that further illustrates Shionogi's expertise in antiviral development.

BPN14770: Targeted for Alzheimer's disease and fragile X syndrome, addressing critical needs in neurological disorders.

Rizmoic: A solution for opioid-induced constipation, improving patient quality of life in pain management.

ADR-001: For decompensated liver cirrhosis, showcasing Shionogi’s innovation in treating serious liver conditions.

SDT-001: A treatment under development for inattentive ADHD, representing a focus on improving mental health and cognitive functions.

In addition to these, Shionogi & Co., Ltd. continues to explore a wide range of therapeutic areas, including treatments for solid tumors, chronic pain, obesity, bladder and esophageal cancer, acute ischemic stroke, depression, and type 2 diabetes. The expansive portfolio underscores Shionogi's commitment to advancing healthcare and improving the lives of patients worldwide.